Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.

Guédon, C; Tauber, M; Linder, C; Paul, C; Shourick, J

Guédon, C; Tauber, M; Linder, C; Paul, C; Shourick, J.

Afiliación

Guédon C; Department of Dermatology, CHU and Université de Toulouse, Toulouse, France. Electronic address: guedon.c@chu-toulouse.fr.
Tauber M; Department of Dermatology, CHU Lyon, Lyon, France.
Linder C; Department of Dermatology, CH Pau, Pau, France.
Paul C; Department of Dermatology, CHU and Université de Toulouse, Toulouse, France.
Shourick J; Department of Epidemiology, Clinical Epidemiology and Public Health, UMR 1027 INSERM-University of Toulouse III, Toulouse University Hospital (CHU), Toulouse, France.

Ann Dermatol Venereol ; 150(3): 215-216, 2023 09.

Article en En | MEDLINE | ID: mdl-37598014

Asunto(s)

Dermatitis Atópica; Humanos; Adulto; Estudios de Cohortes; Dermatitis Atópica/tratamiento farmacológico; Anticuerpos Monoclonales Humanizados/uso terapéutico; Anticuerpos Monoclonales/uso terapéutico; Resultado del Tratamiento; Índice de Severidad de la Enfermedad

Palabras clave

Atopic dermatitis; Dupilumab; Long-term efficacy; Real-world

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dermatitis Atópica Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Ann Dermatol Venereol Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google